| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 4, 2015
World’s Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord...
-
May 20, 2015
Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System...
-
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year.
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
-
Apr 28, 2015MAJESTIC Trial Meets Performance Endpoint With Compelling Results
In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System met...
-
Apr 27, 2015
Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and...
-
Mar 19, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...